1-10 of 10
Jana Moravcova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Musashi 2 mRNA Expression in the Course of CML.

Sylvie Nadvornikova, Marketa Zackova, Tereza Lopotova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2012) 120 (21): 2552.
https://doi.org/10.1182/blood.V120.21.2552.2552
Published: 2012
Journal Articles

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level

Marketa Zackova, Tereza Lopotova, Sylvie Nadvornikova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2011) 118 (21): 4878.
https://doi.org/10.1182/blood.V118.21.4878.4878
Published: 2011
Journal Articles

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work?

Tereza Lopotova, Marketa Zackova, Sylvie Nadvornikova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2011) 118 (21): 4902.
https://doi.org/10.1182/blood.V118.21.4902.4902
Published: 2011
Journal Articles

Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.

Katerina Machova Polakova, Sylvie Nadvornikova, Karla Zemanova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Jiri Mayer, Marek Trneny, Jana Moravcova
Journal: Blood
Blood (2010) 116 (21): 3419.
https://doi.org/10.1182/blood.V116.21.3419.3419
Published: 2010
Journal Articles

Expression Analysis of WT1 Splicing Variants In CML and AML: −5/+KTS as a Novel Candidate for Early Marker of Relapse

Tereza Lopotova, Jaroslav Polak, Hana Klamova, Jiri Schwarz, Jana Moravcova
Journal: Blood
Blood (2010) 116 (21): 2749.
https://doi.org/10.1182/blood.V116.21.2749.2749
Published: 2010
Journal Articles

In Vitro Sensitivity to Tyrosine Kinase Inhibitors Is One of Possible Predictive Parameters for Therapy Switch In Patients with Chronic Myeloid Leukemia

Marketa Zackova, Tereza Lopotova, Zuzana Ondrackova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2010) 116 (21): 2747.
https://doi.org/10.1182/blood.V116.21.2747.2747
Published: 2010
Journal Articles

Detection of BCR-ABL Mutation by High Resolution Melting Analysis Is Affected by the Sequence Content, Position and Type of Nucleotide Change and DNA Dye Together with Salt Composition of PCR Mixes.

Sylvie Nadvornikova, Vaclava Polivkova, Gouse M Shaik, Petr Draber, Jana Moravcova, Katerina Machova Polakova
Journal: Blood
Blood (2009) 114 (22): 1565.
https://doi.org/10.1182/blood.V114.22.1565.1565
Published: 2009
Journal Articles

Expression of Four Major WT1 Splicing Variants in AML and CML: Development of Quantitative Real-Time PCRs and Preliminary Results in Patient Samples.

Tereza Lopotova, Jana Moravcova, Vaclava Polivkova, Jaroslav Polak, Jiri Schwarz, Hana Klamova, Katerina Machova Polakova
Journal: Blood
Blood (2009) 114 (22): 1631.
https://doi.org/10.1182/blood.V114.22.1631.1631
Published: 2009
Journal Articles

The Plateau of BCR-ABL Transcript Level ≥0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.

Katerina Machova Polakova, Vaclava Polivkova, Jana Rulcova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Zdenek Pospisil, Jirí Mayer, Jana Moravcova
Journal: Blood
Blood (2009) 114 (22): 2216.
https://doi.org/10.1182/blood.V114.22.2216.2216
Published: 2009
Journal Articles

Differential Expression of miRNAs during the Course of Chronic Myeloid Leukemia.

Katerina Machova Polakova, Tereza Lopotova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2008) 112 (11): 1082.
https://doi.org/10.1182/blood.V112.11.1082.1082
Published: 2008